


## STATUS OF THE CLAIMS

1. (original) A composition comprising a drug-eluting stent media; wherein said drug-eluting stent media comprises a pharmaceutical composition; wherein said pharmaceutical composition comprises an agent comprising the following formula:



including both R and S enantiomeric forms and racemic mixtures;

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are selected from the group consisting of:

hydrogen; CH<sub>3</sub>; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxy subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein said aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein said aliphatic chain terminates with a carboxylic acid subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one amide subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and

having at least one acyl group; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one nitrogen containing moiety; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one amine subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ether subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one halogen subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one nitronium subgroup;

wherein R5 is selected from the group consisting of: OH; NO<sub>2</sub>; OR'; wherein

R' is selected from the group consisting of:

a linear or branched, saturated or unsaturated aliphatic chain having at least one carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxyl subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein said aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein said aliphatic chain terminates with a carboxylic acid subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one amide subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one acyl group; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one nitrogen containing moiety; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one amine subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one halogen

subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one nitronium subgroup; wherein R6 is selected from the group consisting of: Hyrdrogen; NO<sub>2</sub>; Cl; F; Br; I; SR'; and NR'<sub>2</sub>; wherein R' is defined as above in R5;


wherein R7 is selected from the group consisting of:

Hydrogen; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; and

wherein R8 is an aliphatic cyclic group larger than benzene; wherein said larger than benzene comprises any chemical group containing 7 or more non-hydrogen atoms, and is an aryl or aliphatic cyclic group.

2-5. (canceled).

6. (new) The composition of Claim 1, wherein said agent is




7. (new) The composition of Claim 1, wherein R1, R2, R3 and R4 is H.

8. (new) The composition of Claim 1, wherein R5 is OH.

9. (new) The composition of Claim 1, wherein R6 is Cl.

10. (new) The composition of Claim 1, wherein R7 is CH<sub>3</sub>.



11. (new) The composition of Claim 1, wherein R8 is
12. (new) The composition of Claim 1, wherein said drug-eluting stent media is in contact with a drug-eluting stent.
13. (new) The composition of Claim 12, wherein said drug-eluting stent is seeded with endothelial cells.
14. (new) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anticoagulant drug.
15. (new) The composition of Claim 1, wherein said drug-eluting stent media further comprises an antiplatelet drug.
16. (new) The composition of Claim 1, wherein said drug-eluting stent media further comprises an antimicrobial agent.
17. (new) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anti-inflammatory agent.
18. (new) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anti-metabolic agent.
19. (new) The composition of Claim 1, wherein said drug-eluting stent media further comprises a vasoreactive agent.
20. (new) The composition of Claim 14, wherein said vasoreactive agent is a nitric oxide releasing agent.